Trim 30% via laddered execution into Q1 FY27 print; hold 60% with $88 stop and 4-6 week horizon
Underweight rating maintained with 30% trim executed via laddered approach. The binary Q1 FY27 catalyst this week creates negative near-term asymmetry given stacked macro risks (72% Polymarket hike probability, hawkish Warsh commentary, strengthening dollar with ~50% international revenue exposure) and bearish technical signals. Position capped at 60% of prior weight until catalyst clears and Fed path resolves. Stop at $88.00 (just inside 200 SMA at $88.70) invalidates thesis; evaluate core position separately on breach.
| Position | Action |
|---|---|
| Execute at $91.50 | Trim 10-15% of position |
| Price rallies toward $94.00 on relief bounce | Trim additional 10% |
| Closer to print window | Trim discretionary 5-10% as flow permits |
| Post-Q1 FY27 print with in-line/beat on EPS and constructive FY27 guidance | Upgrade to Hold if stock holds above $88.70 |
| Revenue growth <3% YoY OR forward EPS cut >5% OR soft guidance | Further trim or maintain Underweight |
MDT offers structural alpha from masked earnings power and defensive positioning—revenue has stepped from 2.5% to nearly 10% YoY, forward P/E of 14.15x vs TTM of 24.30x signals the market hasn't priced in normalized earnings, and the stock's low-beta profile with a 3.16% covered dividend makes it the superior defensive rotation in a hawkish Fed regime where peers face operational stumbles.
| Indicator | Value | Signal |
|---|---|---|
| close_10_ema | $91.19 | bearish |
| close_50_sma | $85.41 | bullish |
| close_200_sma | $88.70 | neutral |
| rsi | 55.51 | neutral |
| boll | $90.19 | neutral |
| boll_ub | $95.25 | neutral |
| boll_lb | $85.13 | neutral |
| macd | +1.84 | bullish |
| macds | +2.21 | bearish |
| macdh | -0.37 | bearish |
| atr | $1.99 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Pullback to $88-89 with RSI above 50 on 200 SMA retest
Then: Add to position
↩ rebuts: “Bear's claim that 24x TTM P/E is rich”
EV: +15-25% · concedes: Technical consolidation is real, with price below some short-term moving averages; Total debt of $27.96B is high (though net debt is $25.95B and deleveraging); Tariffs are a real headwind, though global manufacturing footprint provides some insulation; The bear case has the facts—the disagreement is on framework and time horizon
MDT's bull case collapses under scrutiny; technical momentum is failing, macro headwinds (hawkish Fed, tariff escalation, FX drag) work against the stock, and valuation at Forward P/E 14.15x with PEG 1.78 is not undervalued given normalization risk and structural margin pressure.
EV: -$80 (target on next leg down); 15-20% downside more likely than 10-15% upside over 3-6 months · concedes: ISRG premium valuation reflects quality fundamentals, not just market premium; BSX cyberattack/recall is a one-time operational issue, not permanent market share loss; MDT does have strong franchises (cardiovascular, spinal) with durable cash flows; Dividend has been raised through past recessions; Deleveraging is occurring, though at glacial pace ($1.8B over 6 months)
→ vs conservative: Conservative overconfident in fundamentals — dividend raised through two recessions doesn't protect against a bad print combined with hawkish Fed repricing; the $28B debt load and 50% international revenue create direct FX and refinancing drags on the earnings stream supporting that dividend. "That's not analysis, that's faith."
→ vs conservative: A 30% trim into macro fears turning into a 100% loss is the exact scenario conservative thesis ignores; fundamentals cannot be eaten, only sold, and price action signals marginal buyer positioning has shifted.
→ vs neutral: Neutral "wait for confirmation" is a market-timer's trap — confirmation comes AFTER the gap, AFTER the 200 SMA fails, forcing action at $85, $80, or June lows near $73. Mixed signals are precisely when you reduce exposure into binary catalysts.
→ vs neutral: Both conservative (time heals drawdowns) and neutral (clarity comes before the move) are wrong about timing — time does not heal drawdowns when a hawkish Fed repricing and binary earnings event are still ahead.
| vwma | $91.51 | bearish |
Support: 73 · 80 · 82 · 85.13 · 88.7 | Resistance: 91.19 · 91.5 · 94.13 · 95.25 · 98 · 100
MDT has executed a bear-market rally from $73.01 (May 2026 low) to $94.13 (Aug-19), and is now in a consolidation phase sitting just above the critical 200 SMA at $88.70. The short-term trend is stalling with price below the 10 EMA ($91.19) and a negative MACD histogram (–0.37), suggesting the August breakout is losing momentum. Medium-term structure remains supportive with price 6.1% above the 50 SMA, but the 50/200 SMA remain in bearish alignment without a golden cross. Key watch level is $91.50 (bullish trigger) vs. $88.00 (bearish invalidation below 200 SMA).
Market Cap
$116.03B
Share Price (implied)
~$90.66
52-Week High
$106.33
52-Week Low
$73.31
50-Day MA
$85.49
200-Day MA
$89.81
Beta
0.566
P/E (TTM)
24.30x
Forward P/E
14.15x
PEG Ratio
1.78
P/B
2.35x
Dividend Yield
3.16%
EPS (TTM)
$3.73
Forward EPS
$6.40
TTM Revenue
$36.36B
TTM Gross Profit
$23.75B
TTM EBITDA
$10.10B
TTM Net Income
$4.80B
TTM Free Cash Flow
$4.63B
Q4 FY26 Revenue
$9,807M
Q4 FY26 Gross Profit
$6,409M
Q4 FY26 Operating Income
$2,013M
Q4 FY26 Net Income
$1,244M
Q4 FY26 Diluted EPS
$0.96
Q4 FY26 Operating CF
$2,573M
Q4 FY26 Free Cash Flow
$2,085M
Q3 FY26 Revenue
$9,017M
Q3 FY26 Net Income
$1,143M
Q3 FY26 Diluted EPS
$0.89
Q2 FY26 Revenue
$8,961M
Q2 FY26 Net Income
$1,374M
Q2 FY26 Diluted EPS
$1.07
Q1 FY26 Revenue
$8,578M
Q1 FY26 Net Income
$1,040M
Q1 FY26 Diluted EPS
$0.81
Q4 FY25 Revenue
$8,927M
Q4 FY25 Net Income
$1,056M
Q4 FY25 Diluted EPS
$0.82
Gross Margin (TTM)
65.3%
Operating Margin (TTM)
22.05%
Net Margin (TTM)
13.20%
Return on Equity
9.84%
Return on Assets
4.92%
Total Assets
$93,028M
Total Debt
$27,961M
Net Debt
$25.95B
Long-Term Debt
$26,119M
Stockholders' Equity
$49,463M
Cash & ST Investments
$9,220M
Cash & Equivalents
$1,949M
Accounts Receivable
$6,643M
Inventory
$5,951M
Goodwill & Intangibles
$52,733M
Net PPE
$7,417M
Total Liabilities
$42,956M
Working Capital
$13,129M
Current Ratio
2.13x
Debt/Equity
58.21
Book Value per Share
$38.64/share
Q4 FY26 Dividends Paid
$908M
Q4 FY26 Buybacks
$435M
Q4 FY26 Total Capital Returns
$1.34B
Q1 FY26 Restructuring/M&A Charges
$45M
Q2 FY26 Restructuring/M&A Charges
$10M
Q3 FY26 Restructuring/M&A Charges
$77M
Q4 FY26 Restructuring/M&A Charges
$118M
Q4 FY25 Restructuring/M&A Charges
$147M
Q3 FY26 Effective Tax Rate
31.4%
Q2 FY26 Effective Tax Rate
18.1%
Annualized CapEx
$1.9B
Strengths
Concerns
Medtronic (MDT) is a high-quality, defensive mega-cap medtech franchise with re-accelerating top-line growth (from 2.5% to 9.8% YoY), premium 65% gross margins, and a $4.6B annualized FCF base. The current TTM P/E appears elevated at 24.3x due to one-time restructuring charges ($10M-$147M/quarter), but the forward P/E of ~14.15x implies meaningful earnings normalization ahead with 72% YoY EPS growth expected. The company carries significant debt ($27.96B total, $25.95B net) with a 58.2% debt/equity ratio, though active deleveraging is underway. With a 3.16% dividend yield, low 0.57 beta, and inventory building worth monitoring, MDT offers an attractive risk-adjusted profile for income- and quality-focused investors.
Macro: Hawkish Fed regime confirmed by prediction markets and Barchart citing Fed Chair Kevin Warsh's hawkish Jackson Hole comments. Polymarket odds show 72% probability of a 2026 rate hike (+15.0pp weekly), 56% odds by September (+22.0pp), and 88% odds of zero cuts in 2026. US recession odds at just 8%, supporting intact hospital capex and elective procedure volumes. Renewed US-Iran hostilities widening the risk-off bid for defensive sectors. No FRED macro data available—all macro commentary derived from news, prediction markets, and Barchart.